Advertisement

Heart Failure Reviews

, Volume 24, Issue 6, pp 1031–1040 | Cite as

Research progress on the pathogenesis of CTEPH

  • Lu Yan
  • Xin Li
  • Zhihong LiuEmail author
  • Zhihui Zhao
  • Qin Luo
  • Qin Zhao
  • Qi Jin
  • Xue Yu
  • Yi Zhang
Article

Abstract

Chronic thromboembolic pulmonary hypertension (CTEPH) is an established long-term complication of pulmonary thromboembolism (PTE). However, studies have shown that many patients with a definitive CTEPH diagnosis have no history of symptomatic PTE, suggesting that PTE is not the only cause of CTEPH. Despite extensive progress in research on pulmonary hypertension in recent years, due to a lack of relevant studies on the pathophysiology of CTEPH, implementing pulmonary endarterectomy (PEA) in patients has many challenges, and the prognosis of patients with CTEPH is still not optimistic. Therefore, revealing the pathogenesis of CTEPH would be of great significance for understanding the occurrence and development of CTEPH, developing relevant drug treatment studies and formulating intervention strategies, and may provide new preventive measures. This article summarizes the current research progress in CTEPH pathogenesis from the perspective of risk factors related to medical history, abnormal coagulation and fibrinolytic mechanisms, inflammatory mechanisms, genetic susceptibility factors, angiogenesis, in situ thrombosis, vascular remodeling, and other aspects.

Keywords

Thromboembolism Pulmonary hypertension Pathogenesis 

Notes

Compliance with ethical standards

Conflict of interest

The authors have no conflicts of interest to declare.

References

  1. 1.
    Opitz C, Rosenkranz S, Ghofrani HA, Grünig E, Klose H, Olschewski H, Hoeper M (2016) ESC guidelines 2015 pulmonary hypertension: diagnosis and treatment. Dtsch Med Wochenschr 141(24):1764–1769PubMedPubMedCentralGoogle Scholar
  2. 2.
    Lang IM, Pesavento R, Bonderman D, Yuan JX (2013) Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding. Eur Respir J 41(2):462–468PubMedGoogle Scholar
  3. 3.
    Elwing JM, Vaidya A, Auger WR (2018) Chronic thromboembolic pulmonary hypertension: An Update. Clin Chest Med 39(3):605–620PubMedGoogle Scholar
  4. 4.
    Gall H, Hoeper MM, Richter MJ, Cacheris W, Hinzmann B, Mayer E (2017) An epidemiological analysis of the burden of chronic thromboembolic pulmonary hypertension in the USA, Europe and Japan. Eur Respir Rev 26(143):160121PubMedGoogle Scholar
  5. 5.
    Tapson VF, Platt DM, Xia F, Teal SA, de la Orden M, Divers CH, Satler CA, Joish VN, Channick RN (2016) Monitoring for pulmonary hypertension following pulmonary embolism: the INFORM study. Am J Med 129(9):978–985 e972 PubMedGoogle Scholar
  6. 6.
    Pengo V, Lensing AW, Prins MH, Marchiori A, Davidson BL, Tiozzo F, Albanese P, Biasiolo A, Pegoraro C, Iliceto S, Prandoni P, Thromboembolic Pulmonary Hypertension Study Group (2004) Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 350(22):2257–2264PubMedGoogle Scholar
  7. 7.
    Yang S, Yang Y, Zhai Z, Kuang T, Gong J, Zhang S, Zhu J, Liang L, Shen YH, Wang C (2015) Incidence and risk factors of chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolism. J Thorac Dis 7(11):1927–1938PubMedPubMedCentralGoogle Scholar
  8. 8.
    Escribano-Subias P, Blanco I, Lopez-Meseguer M et al (2012) Survival in pulmonary hypertension in Spain: insights from the Spanish registry. Eur Respir J 40(3):596–603PubMedGoogle Scholar
  9. 9.
    Fernandes T, Auger W, Fedullo P (2018) Epidemiology and risk factors for chronic thromboembolic pulmonary hypertension. Thromb Res 164:145–149PubMedGoogle Scholar
  10. 10.
    Woo K, Tse L, Tse C, Metreweli C, Vallance-Owen J (1988) The prevalence and pattern of pulmonary thromboembolism in the Chinese in Hong Kong. Int J Cardiol 20(3):373–380PubMedGoogle Scholar
  11. 11.
    Yang Y, Liang L, Zhai Z, He H, Xie W, Peng X, Wang C, on behalf of investigators for the National Cooperative Project for the Prevention and Treatment of PTE-DVT (2011) Pulmonary embolism incidence and fatality trends in Chinese hospitals from 1997 to 2008: a multicenter registration study. PLoS One 6(11):e26861PubMedPubMedCentralGoogle Scholar
  12. 12.
    Pepke-Zaba J, Delcroix M, Lang I, Mayer E, Jansa P, Ambroz D, Treacy C, D'Armini AM, Morsolini M, Snijder R, Bresser P, Torbicki A, Kristensen B, Lewczuk J, Simkova I, Barberà JA, de Perrot M, Hoeper MM, Gaine S, Speich R, Gomez-Sanchez MA, Kovacs G, Hamid AM, Jaïs X, Simonneau G (2011) Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation 124(18):1973–1981PubMedGoogle Scholar
  13. 13.
    Al-Naamani N, Espitia HG, Velazquez-Moreno H et al (2016) Chronic thromboembolic pulmonary hypertension: experience from a single center in Mexico. Lung 194(2):315–323PubMedPubMedCentralGoogle Scholar
  14. 14.
    Riedel M, Stanek V, Widimsky J, Prerovsky I (1982) Longterm follow-up of patients with pulmonary thromboembolism. Late prognosis and evolution of hemodynamic and respiratory data. Chest 81(2):151–158PubMedGoogle Scholar
  15. 15.
    Lewczuk J, Piszko P, Jagas J, Porada A, Sobkowicz B, Wrabec K, Wójciak S (2001) Prognostic factors in medically treated patients with chronic pulmonary embolism. Chest 119(3):818–823PubMedGoogle Scholar
  16. 16.
    Auger WR, Kim NH, Trow TK (2010) Chronic thromboembolic pulmonary hypertension. Clin Chest Med 31(4):741–758PubMedGoogle Scholar
  17. 17.
    Egermayer P, Peacock AJ (2000) Is pulmonary embolism a common cause of chronic pulmonary hypertension? Limitations of the embolic hypothesis. Eur Respir J 15(3):440–448PubMedGoogle Scholar
  18. 18.
    Lang IM, Marsh JJ, Konopka RG, Olman MA, Binder BR, Moser KM, Schleef RR (1993) Factors contributing to increased vascular fibrinolytic activity in mongrel dogs. Circulation 87(6):1990–2000PubMedGoogle Scholar
  19. 19.
    Lang IM, Marsh J, Moser K, Schleef R (1992) Presence of active and latent type 1 plasminogen activator inhibitor associated with porcine platelets. Blood 80(9):2269–2274PubMedGoogle Scholar
  20. 20.
    Fedullo PF, Auger WR, Kerr KM, Rubin LJ (2001) Chronic thromboembolic pulmonary hypertension. N Engl J Med 345(20):1465–1472PubMedGoogle Scholar
  21. 21.
    Pesavento R, Filippi L, Palla A, Visonà A, Bova C, Marzolo M, Porro F, Villalta S, Ciammaichella M, Bucherini E, Nante G, Battistelli S, Muiesan ML, Beltramello G, Prisco D, Casazza F, Ageno W, Palareti G, Quintavalla R, Monti S, Mumoli N, Zanatta N, Cappelli R, Cattaneo M, Moretti V, Corà F, Bazzan M, Ghirarduzzi A, Frigo AC, Miniati M, Prandoni P, SCOPE Investigators (2017) Impact of residual pulmonary obstruction on the long-term outcome of patients with pulmonary embolism. Eur Respir J 49(5):1601980PubMedGoogle Scholar
  22. 22.
    Yamaki S, Ando M, Fukumoto Y, Higuchi Y, Kaneko K, Maeda K, Shimokawa H (2014) Histopathological examination by lung biopsy for the evaluation of operability and postoperative prognosis in patients with chronic thromboembolic pulmonary hypertension. Circ J 78(2):476–482PubMedGoogle Scholar
  23. 23.
    Lang IM, Madani M (2014) Update on chronic thromboembolic pulmonary hypertension. Circulation 130(6):508–518PubMedGoogle Scholar
  24. 24.
    Edward JA, Mandras S (2017) An update on the management of chronic thromboembolic pulmonary hypertension. Curr Probl Cardiol 42(1):7–38PubMedGoogle Scholar
  25. 25.
    Miniati M, Monti S, Bottai M, Scoscia E, Bauleo C, Tonelli L, Dainelli A, Giuntini C (2006) Survival and restoration of pulmonary perfusion in a long-term follow-up of patients after acute pulmonary embolism. Medicine (Baltimore) 85(5):253–262Google Scholar
  26. 26.
    Becattini C, Agnelli G, Pesavento R, Silingardi M, Poggio R, Taliani MR, Ageno W (2006) Incidence of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism. Chest 130(1):172–175PubMedGoogle Scholar
  27. 27.
    Klok FA, van Kralingen KW, van Dijk AP, Heyning FH, Vliegen HW, Huisman MV (2010) Prospective cardiopulmonary screening program to detect chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolism. Haematologica 95(6):970–975PubMedPubMedCentralGoogle Scholar
  28. 28.
    Poli D, Grifoni E, Antonucci E, Arcangeli C, Prisco D, Abbate R, Miniati M (2010) Incidence of recurrent venous thromboembolism and of chronic thromboembolic pulmonary hypertension in patients after a first episode of pulmonary embolism. J Thromb Thrombolysis 30(3):294–299PubMedGoogle Scholar
  29. 29.
    Guerin L, Couturaud F, Parent F et al (2014) Prevalence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. Prevalence of CTEPH after pulmonary embolism. Thromb Haemost 112(3):598–605PubMedGoogle Scholar
  30. 30.
    Otero R, Oribe M, Ballaz A, Jimenez D, Uresandi F, Nauffal D, Conget F, Rodriguez C, Elias T, Jara L, Cayuela A, Blanco I, Barberá J (2011) Echocardiographic assessment of pulmonary arterial pressure in the follow-up of patients with pulmonary embolism. Thromb Res 127(4):303–308PubMedGoogle Scholar
  31. 31.
    Dentali F, Donadini M, Gianni M, Bertolini A, Squizzato A, Venco A, Ageno W (2009) Incidence of chronic pulmonary hypertension in patients with previous pulmonary embolism. Thromb Res 124(3):256–258PubMedGoogle Scholar
  32. 32.
    Korkmaz A, Ozlu T, Ozsu S, Kazaz Z, Bulbul Y (2012) Long-term outcomes in acute pulmonary thromboembolism: the incidence of chronic thromboembolic pulmonary hypertension and associated risk factors. Clin Appl Thromb Hemost 18(3):281–288PubMedGoogle Scholar
  33. 33.
    Fedullo P, Kerr KM, Kim NH, Auger WR (2011) Chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 183(12):1605–1613PubMedGoogle Scholar
  34. 34.
    Bonderman D, Wilkens H, Wakounig S, Schäfers HJ, Jansa P, Lindner J, Simkova I, Martischnig AM, Dudczak J, Sadushi R, Skoro-Sajer N, Klepetko W, Lang IM (2009) Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir J 33(2):325–331PubMedGoogle Scholar
  35. 35.
    Bonderman D, Jakowitsch J, Adlbrecht C, Schemper M, Kyrle P, Schönauer V, Exner M, Klepetko W, Kneussl M, Maurer G, Lang I (2005) Medical conditions increasing the risk of chronic thromboembolic pulmonary hypertension. Thromb Haemost 93(3):512–516PubMedGoogle Scholar
  36. 36.
    Kim NH, Lang IM (2012) Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir Rev 21(123):27–31PubMedGoogle Scholar
  37. 37.
    Kyrle PA, Minar E, Hirschl M, Bialonczyk C, Stain M, Schneider B, Weltermann A, Speiser W, Lechner K, Eichinger S (2000) High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 343(7):457–462PubMedGoogle Scholar
  38. 38.
    Bonderman D, Turecek PL, Jakowitsch J, Weltermann A, Adlbrecht C, Schneider B, Kneussl M, Rubin L, Kyrle P, Klepetko W, Maurer G, Lang I (2003) High prevalence of elevated clotting factor VIII in chronic thromboembolic pulmonary hypertension. Thromb Haemost 90(3):372–376PubMedGoogle Scholar
  39. 39.
    Lisman T, de Groot PG, Meijers JC, Rosendaal FR (2005) Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood 105(3):1102–1105PubMedGoogle Scholar
  40. 40.
    Morris TA (2013) Why acute pulmonary embolism becomes chronic thromboembolic pulmonary hypertension: clinical and genetic insights. Curr Opin Pulm Med 19(5):422–429PubMedGoogle Scholar
  41. 41.
    Ghosh AK, Vaughan DE (2012) PAI-1 in tissue fibrosis. J Cell Physiol 227(2):493–507PubMedPubMedCentralGoogle Scholar
  42. 42.
    Vuylsteke A, Sharples L, Charman G, Kneeshaw J, Tsui S, Dunning J, Wheaton E, Klein A, Arrowsmith J, Hall R, Jenkins D (2011) Circulatory arrest versus cerebral perfusion during pulmonary endarterectomy surgery (PEACOG): a randomised controlled trial. Lancet 378(9800):1379–1387PubMedGoogle Scholar
  43. 43.
    Lang IM, Marsh JJ, Olman MA, Moser KM, Schleef RR (1994) Parallel analysis of tissue-type plasminogen activator and type 1 plasminogen activator inhibitor in plasma and endothelial cells derived from patients with chronic pulmonary thromboemboli. Circulation 90(2):706–712PubMedGoogle Scholar
  44. 44.
    Morris TA, Marsh JJ, Chiles PG, Auger WR, Fedullo PF, Woods VL Jr (2006) Fibrin derived from patients with chronic thromboembolic pulmonary hypertension is resistant to lysis. Am J Respir Crit Care Med 173(11):1270–1275PubMedPubMedCentralGoogle Scholar
  45. 45.
    Morris TA, Marsh JJ, Chiles PG, Magana MM, Liang NC, Soler X, DeSantis DJ, Ngo D, Woods VL (2009) High prevalence of dysfibrinogenemia among patients with chronic thromboembolic pulmonary hypertension. Blood 114(9):1929–1936PubMedPubMedCentralGoogle Scholar
  46. 46.
    Miniati M, Fiorillo C, Becatti M, Monti S, Bottai M, Marini C, Grifoni E, Formichi B, Bauleo C, Arcangeli C, Poli D, Nassi PA, Abbate R, Prisco D (2010) Fibrin resistance to lysis in patients with pulmonary hypertension other than thromboembolic. Am J Respir Crit Care Med 181(9):992–996PubMedGoogle Scholar
  47. 47.
    Suntharalingam J, Goldsmith K, van Marion V, Long L, Treacy CM, Dudbridge F, Toshner MR, Pepke-Zaba J, Eikenboom JCJ, Morrell NW (2008) Fibrinogen Aalpha Thr312Ala polymorphism is associated with chronic thromboembolic pulmonary hypertension. Eur Respir J 31(4):736–741PubMedGoogle Scholar
  48. 48.
    Standeven KF, Grant PJ, Carter AM, Scheiner T, Weisel JW, Ariens RA (2003) Functional analysis of the fibrinogen Aalpha Thr312Ala polymorphism: effects on fibrin structure and function. Circulation 107(18):2326–2330PubMedGoogle Scholar
  49. 49.
    Kellermair J, Redwan B, Alias S, Jabkowski J, Panzenboeck A, Kellermair L, Winter MP, Weltermann A, Lang IM (2013) Platelet endothelial cell adhesion molecule 1 deficiency misguides venous thrombus resolution. Blood 122(19):3376–3384PubMedGoogle Scholar
  50. 50.
    Bonderman D, Jakowitsch J, Redwan B, Bergmeister H, Renner MK, Panzenböck H, Adlbrecht C, Georgopoulos A, Klepetko W, Kneussl M, Lang IM (2008) Role for staphylococci in misguided thrombus resolution of chronic thromboembolic pulmonary hypertension. Arterioscler Thromb Vasc Biol 28(4):678–684PubMedGoogle Scholar
  51. 51.
    Zabini D, Heinemann A, Foris V, Nagaraj C, Nierlich P, Bálint Z, Kwapiszewska G, Lang IM, Klepetko W, Olschewski H, Olschewski A (2014) Comprehensive analysis of inflammatory markers in chronic thromboembolic pulmonary hypertension patients. Eur Respir J 44(4):951–962PubMedGoogle Scholar
  52. 52.
    Quarck R, Nawrot T, Meyns B, Delcroix M (2009) C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension. J Am Coll Cardiol 53(14):1211–1218PubMedGoogle Scholar
  53. 53.
    Cohn DM, Roshani S, Middeldorp S (2007) Thrombophilia and venous thromboembolism: implications for testing. Semin Thromb Hemost 33(6):573–581PubMedGoogle Scholar
  54. 54.
    Wolf M, Boyer-Neumann C, Parent F, Eschwege V, Jaillet H, Meyer D, Simonneau G (2000) Thrombotic risk factors in pulmonary hypertension. Eur Respir J 15(2):395–399PubMedGoogle Scholar
  55. 55.
    Wong CL, Szydlo R, Gibbs S, Laffan M (2010) Hereditary and acquired thrombotic risk factors for chronic thromboembolic pulmonary hypertension. Blood Coagul Fibrinolysis 21(3):201–206PubMedGoogle Scholar
  56. 56.
    Lotta LA, Tuana G, Yu J, Martinelli I, Wang M, Yu F, Passamonti SM, Pappalardo E, Valsecchi C, Scherer SE, Hale W IV, Muzny DM, Randi G, Rosendaal FR, Gibbs RA, Peyvandi F (2013) Next-generation sequencing study finds an excess of rare, coding single-nucleotide variants of ADAMTS13 in patients with deep vein thrombosis. J Thromb Haemost 11(7):1228–1239PubMedGoogle Scholar
  57. 57.
    Orstavik KH, Magnus P, Reisner H, Berg K, Graham JB, Nance W (1985) Factor VIII and factor IX in a twin population. Evidence for a major effect of ABO locus on factor VIII level. Am J Hum Genet 37(1):89–101PubMedPubMedCentralGoogle Scholar
  58. 58.
    Ma Q, Jacobi PM, Emmer BT, Kretz CA, Ozel AB, McGee B, Kimchi-Sarfaty C, Ginsburg D, Li JZ, Desch KC (2017) Genetic variants in ADAMTS13 as well as smoking are major determinants of plasma ADAMTS13 levels. Blood Adv 1(15):1037–1046PubMedPubMedCentralGoogle Scholar
  59. 59.
    Chion CK, Doggen CJ, Crawley JT, Lane DA, Rosendaal FR (2007) ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men. Blood 109(5):1998–2000PubMedGoogle Scholar
  60. 60.
    Newnham M, South K, Bleda M, Auger WR, Barberà JA, Bogaard H, Bunclark K, Cannon JE, Delcroix M, Hadinnapola C, Howard LS, Jenkins D, Mayer E, Ng C, Rhodes CJ, Screaton N, Sheares K, Simpson MA, Southwood M, Su L, Taboada D, Traylor M, Trembath RC, Villar SS, Wilkins MR, Wharton J, Gräf S, Pepke-Zaba J, Laffan M, Lane DA, Morrell NW, Toshner M (2019) The ADAMTS13–VWF axis is dysregulated in chronic thromboembolic pulmonary hypertension. Eur Respir J 53(3):1801805PubMedPubMedCentralGoogle Scholar
  61. 61.
    Feng YX, Liu D, Sun ML, Jiang X, Sun N, Mao YM, Jing ZC (2014) BMPR2 germline mutation in chronic thromboembolic pulmonary hypertension. Lung 192(4):625–627PubMedGoogle Scholar
  62. 62.
    Ulrich S, Szamalek-Hoegel J, Hersberger M, Fischler M, Garcia JS, Huber LC, Grünig E, Janssen B, Speich R (2010) Sequence variants in BMPR2 and genes involved in the serotonin and nitric oxide pathways in idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: relation to clinical parameters and comparison with left heart disease. Respiration 79(4):279–287PubMedGoogle Scholar
  63. 63.
    Distler JH, Hirth A, Kurowska-Stolarska M, Gay RE, Gay S, Distler O (2003) Angiogenic and angiostatic factors in the molecular control of angiogenesis. Q J Nucl Med 47(3):149–161PubMedGoogle Scholar
  64. 64.
    Waltham M, Burnand KG, Collins M, Smith A (2000) Vascular endothelial growth factor and basic fibroblast growth factor are found in resolving venous thrombi. J Vasc Surg 32(5):988–996PubMedGoogle Scholar
  65. 65.
    Henke PK, Wakefield TW, Kadell AM, Linn MJ, Varma MR, Sarkar M, Hawley A, Fowlkes JB, Strieter RM (2001) Interleukin-8 administration enhances venous thrombosis resolution in a rat model. J Surg Res 99(1):84–91PubMedGoogle Scholar
  66. 66.
    Yaoita N, Shirakawa R, Fukumoto Y, Sugimura K, Miyata S, Miura Y, Nochioka K, Miura M, Tatebe S, Aoki T, Yamamoto S, Satoh K, Kimura T, Shimokawa H, Horiuchi H (2014) Platelets are highly activated in patients of chronic thromboembolic pulmonary hypertension. Arterioscler Thromb Vasc Biol 34(11):2486–2494PubMedGoogle Scholar
  67. 67.
    Moser KM, Bloor CM (1993) Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension. Chest 103(3):685–692PubMedGoogle Scholar
  68. 68.
    Lang IM, Marsh JJ, Olman MA, Moser KM, Loskutoff DJ, Schleef RR (1994) Expression of type 1 plasminogen activator inhibitor in chronic pulmonary thromboemboli. Circulation 89(6):2715–2721PubMedGoogle Scholar
  69. 69.
    Sakao S, Tatsumi K (2013) Crosstalk between endothelial cell and thrombus in chronic thromboembolic pulmonary hypertension: perspective. Histol Histopathol 28(2):185–193PubMedGoogle Scholar
  70. 70.
    Sakao S, Hao H, Tanabe N, Kasahara Y, Kurosu K, Tatsumi K (2011) Endothelial-like cells in chronic thromboembolic pulmonary hypertension: crosstalk with myofibroblast-like cells. Respir Res 12:109PubMedPubMedCentralGoogle Scholar
  71. 71.
    Firth AL, Yao W, Ogawa A, Madani MM, Lin GY, Yuan JX (2010) Multipotent mesenchymal progenitor cells are present in endarterectomized tissues from patients with chronic thromboembolic pulmonary hypertension. Am J Physiol Cell Physiol 298(5):C1217–C1225PubMedPubMedCentralGoogle Scholar
  72. 72.
    Zabini D, Nagaraj C, Stacher E, Lang IM, Nierlich P, Klepetko W, Heinemann A, Olschewski H, Bálint Z, Olschewski A (2012) Angiostatic factors in the pulmonary endarterectomy material from chronic thromboembolic pulmonary hypertension patients cause endothelial dysfunction. PLoS One 7(8):e43793PubMedPubMedCentralGoogle Scholar
  73. 73.
    Firth AL, Yau J, White A, Chiles PG, Marsh JJ, Morris TA, Yuan JXJ (2009) Chronic exposure to fibrin and fibrinogen differentially regulates intracellular Ca2+ in human pulmonary arterial smooth muscle and endothelial cells. Am J Physiol Lung Cell Mol Physiol 296(6):L979–L986PubMedPubMedCentralGoogle Scholar
  74. 74.
    Rhodes CJ, Im H, Cao A, Hennigs JK, Wang L, Sa S, Chen PI, Nickel NP, Miyagawa K, Hopper RK, Tojais NF, Li CG, Gu M, Spiekerkoetter E, Xian Z, Chen R, Zhao M, Kaschwich M, del Rosario PA, Bernstein D, Zamanian RT, Wu JC, Snyder MP, Rabinovitch M (2015) RNA sequencing analysis detection of a novel pathway of endothelial dysfunction in pulmonary arterial hypertension. Am J Respir Crit Care Med 192(3):356–366PubMedPubMedCentralGoogle Scholar
  75. 75.
    Abdul-Salam VB, Wharton J, Cupitt J, Berryman M, Edwards RJ, Wilkins MR (2010) Proteomic analysis of lung tissues from patients with pulmonary arterial hypertension. Circulation 122(20):2058–2067PubMedGoogle Scholar
  76. 76.
    Hemnes AR, Trammell AW, Archer SL, Rich S, Yu C, Nian H, Penner N, Funke M, Wheeler L, Robbins IM, Austin ED, Newman JH, West J (2015) Peripheral blood signature of vasodilator-responsive pulmonary arterial hypertension. Circulation. 131(4):401–409 discussion 409 PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Lu Yan
    • 1
  • Xin Li
    • 1
  • Zhihong Liu
    • 1
    Email author
  • Zhihui Zhao
    • 1
  • Qin Luo
    • 1
  • Qin Zhao
    • 1
  • Qi Jin
    • 1
  • Xue Yu
    • 1
  • Yi Zhang
    • 1
  1. 1.Center for Pulmonary Vascular Diseases, Fuwai Hospital, National Center for Cardiovascular DiseasesChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina

Personalised recommendations